PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) is one of the four subunits of the 110kDa catalytic domain of PI3K protein, which contains a regulatory region of 85kDa. PI3K proteins form a family of lipid kinases. This gene is localized to human chromosome 3q.

Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α-isoform recombinant protein epitope signature tag (PrEST)

Anti-PIK3CA antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project . Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.

PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) is one of the four catalytic subunits of PI3K protein, which plays an essential role in extracellular growth signaling. It phosphorylates and activates protein kinase B (PKB) protein. This protein has a wide range of physiological functions, and plays central role in multiple types of cancers. PIK3CA gene is either mutated or amplified in brain, breast, stomach, liver, ovary and colon cancers. Mutation in this gene leads to enhanced PI3K activity, and it is a candidate transforming oncogene. It is over-expressed in invasive breast cancer and is a marker for poor prognosis. This gene is amplified in high-grade dysplastic lesions from bronchial biopsy specimens obtained from preinvasive squamous lung cancer. Frequency of mutations in PIK3CA gene is higher in tumors without lymph node metastasis, than those within gastric cancer. Thus, it might be essential to evaluate the mutations in this gene to determine cetuximab treatment in gastric cancer patients.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Corresponding Antigen APREST86825.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.